HIV, Hepatitis B virus (HBV) and hepatitis C virus (HCV) are blood- borne infections (BBIs) readily spread by injection equipment contaminated with blood and other body fluids. Exposures to unsafe injections during health–care are the leading cause of new HCV infections globally. Improvements in infection control by clinical care systems and use of auto-disable (AD) syringes by pediatric immunization programs reduced the risk of HCV infection and other BBIs. However, the rapid introduction and scale-up of COVID-19 vaccination in low-and middle-income countries (LMICs), while a welcomed addition to the pandemic response, pose new risks for exposures to blood contaminated injection equipment and the resurgence of BBIs. Leading public health officials recently raised concerns regarding injection safety of COVID-19 vaccination programs (1).
At least three factors increase the potential for unsafe injections during mass COVID-19 vaccination particularly in low and middle income countries (LMICs). First, the supply of auto-disposable syringes might not meet the demand for COVID-19 vaccination. Over the remainder of 2021 and through 2022, an estimated 15 b-19 b doses of COVID-19 are expected to be delivered. This number of vaccinations will require massive increases in syringe supply, distribution with ready availability at the site of vaccination. While models estimate existing supplies of AD syringes are sufficient in the short term, more production of AD syringes is needed to meet demands for COVID-19 vaccination in 2022. UNICEF Executive Director Henrietta Fore has expressed concern regarding the coming shortage of COVID-19 vaccine syringes particularly for LMICs where auto-disposable syringes are critical for injection safety (2). Dr. Matshidiso Moeti, director of the WHO regional office in Africa recently raised this alarm: “Unless drastic measures are taken to boost syringe production, Africa faces a crisis." (3) Secondly, syringe production is complex for COVID-19 vaccines. Different syringes are needed to deliver vaccine doses which vary by type of COVID-19 vaccine. The Pfizer-BioNTech vaccine requires 0.3-mL dose. This syringe is made by a limited number of manufacturers with no reserve in a global stockpile. The Oxford-AstraZeneca vaccine and others require 0.5-mL doses. As AD syringes are typically designed to provide a preset 0.5-ml dosage only, additional manufacture of a 0.3 mL dose is needed to meet the demand for this type of syringe while avoiding declines in production of 0.5 mL syringes. Thirdly, the rapid scale-up of COVID-19 vaccination can exceed the capacity of current pediatric and adolescent vaccination programs; most countries do not have adult vaccination programs. Governments will seek to rapidly achieve high immunization coverage among adults. In most countries, public demand for vaccination is high. To achieve high COVID-19 vaccination coverage will often require recruitment of adult care providers and other clinical staff who have not previously participated in vaccination programs. These staff must receive training in injection of vaccinations. The demands on governments and their vaccination programs can also place pressure to use available vaccines even if injection safety is compromised. Dr. Sabin Nsanzimana, director-general at the Rwanda Biomedical Centre, recently reported some vaccines are received less than a month before expiration (3). To mitigate the transmission risks of BBIs, COVID-19 immunization campaigns must assure a reliable supply of safe injection equipment, and the program management and clinical training to assure COVID-19 vaccines are safe. Necessary steps to assure safe injections of COVID-19 vaccines include:
The Task Force for Global Health can create a community of practice for national COVID-19 vaccination programs to share their injections safety plans, procedures and evaluations. 1) Chan M, Dzau V, Jha A, Hunt J, Kelley E, Zeltner T. The global vaccine effort will be a hollow victory if it leads to unsafe injection practices. Washington Post. July 19, 2021 https://www.washingtonpost.com/opinions/2021/07/19/global-vaccine-effort-would-be-hollow-victoryif-it-leads-unsafe-injection-practices/ accessed October 28,2021 2) Urgent action needed now to ensure sufficient COVID vaccine syringe supply to meet 2022 vaccination targets. Unicef https://www.unicef.org/press-releases/urgent-action-needed-now-ensuresufficient-covid-vaccine-syringe-supply-meet-2022 accessed October 28, 2021 3) Jerving J. Looming syringe crisis threatens COVID-19 vaccine efforts in Africa, Devex. https://www.devex.com/news/looming-syringe-crisis-threatens-covid-19-vaccine-efforts-in-africa101948?access_key=&utm_source=nl_newswire&utm_term=article&utm_content=cta&mkt_tok=Njg1L UtCTC03NjUAAAGAarIOICftu4p4DMHzRQ2mZKHx-DfvbcSzWConANB1EBcoaDakMnVvmHPS8pzqo2Oe_9HPSLXTwqV3onH4lVn27mFNx86Rldq9f898fLH8PHLNuY accessed October 28,2021
Hepatitis B, Hepatitis C and HIV are the 3 main blood borne viruses (BBVs). They are transmitted through:
The risk of being exposed to a BBV infection is increased by:
You can also be exposed to BBVs through medical treatment, particularly in countries with limited medical facilities or less strict infection control and hygiene practices. Types of travel that can increase your risk of requiring medical treatment might include: Recommendations for TravellersAll BBVs are transmitted in the same way. Even if you are vaccinated against Hepatitis B, you should still take preventative steps to reduce your risk of exposure to Hepatitis C and HIV:
Blood transfusion
VaccinationHepatitis B vaccine should be considered if you may be at risk of exposure. This should be discussed with your travel health advisor. There is no vaccine against Hepatitis C or HIV. The IllnessInitial infection with a BBV may cause no symptoms or can produce an initial severe illness. Although initial infection with Hepatitis B and C may spontaneously clear, all 3 BBVs can cause life-long infection. Hepatitis C infection can be cured with oral treatment. Chronic Hepatitis B infection and HIV infection cannot be cured but the life-long infection can be controlled with treatment. Further InformationThe Blood Care Foundation is an organisation which aims to make reliably screened blood, blood products and sterile equipment available to its members in case of emergency. The Foundation uses a network of internationally recognised sources, from where screened blood can be dispatched to members anywhere in the world in an emergency. However this does not usually help with an immediate need for blood transfusion, for example, after massive blood loss in an accident.
back to top |